Insights

Innovative Therapeutics Sylentis specializes in gene silencing therapies for ophthalmologic conditions like glaucoma and dry eye syndrome, making it a prime candidate for collaborations in cutting-edge biotech and pharmaceutical R&D partnerships seeking novel treatments.

Strategic Ownership As a wholly owned subsidiary of PharmaMar, Sylentis benefits from established industry support and resources, providing opportunities for joint ventures or co-development initiatives in innovative gene therapy platforms.

Leadership Appointment Recent appointment of a new CEO indicates strategic leadership shifts, which could signal potential changes in company focus or expansion plans, presenting opportunities to introduce complementary technologies or services.

Growth Potential With recent revenue estimates ranging from 1M to 10M and a focused pipeline in ophthalmology, Sylentis presents growth opportunities for suppliers of advanced biotech tools, clinical trial services, or therapeutic delivery technology.

Technology Stack Compatibility Utilizing popular platforms like WordPress, Google Analytics, and Bootstrap suggests openness to digital engagement and technology upgrades, offering prospects for software solutions, digital marketing services, or data analytics tools tailored for biotech companies.

SYLENTIS Tech Stack

SYLENTIS uses 8 technology products and services including WordPress, Microsoft 365, Google Fonts API, and more. Explore SYLENTIS's tech stack below.

WordPress

Content Management System

Microsoft 365

Google Fonts API

Font Scripts

spin.js

Javascript Frameworks

Isotope

Javascript Libraries

DPD

Logistics

Bootstrap

UI Frameworks

Google Analytics

Web Analytics

SYLENTIS Email Formats	Example	Percentage
FLast@sylentis.com	JDoe@sylentis.com	50%
FLast@sylentis.com	JDoe@sylentis.com	50%

SYLENTIS Email Formats

Example

Percentage

FLast@sylentis.com

JDoe@sylentis.com

50%

FLast@sylentis.com

JDoe@sylentis.com

50%

Frequently Asked Questions

What is SYLENTIS's phone number?

You can contact SYLENTIS's main corporate office by phone at

+34-918-04-7****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is SYLENTIS's official website and social media links?

SYLENTIS's official website is sylentis.com and has social profiles on LinkedIn Crunchbase.

What is SYLENTIS's SIC code NAICS code?

SYLENTIS's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does SYLENTIS have currently?

As of January 2026, SYLENTIS has approximately 55 employees across 1 continents, including Europe. Key team members include Chief Executive Officer: A. S.Head Of Clinical Operations: A. B.Laboratory Head - Molecular And Cell Biology: F. R. O.. Explore SYLENTIS's employee directory with LeadIQ.

What industry does SYLENTIS belong to?

SYLENTIS operates in the Biotechnology Research industry.

What technology does SYLENTIS use?

SYLENTIS's tech stack includes WordPressMicrosoft 365Google Fonts APIspin.jsIsotopeDPDBootstrapGoogle Analytics.

What is SYLENTIS's email format?

SYLENTIS's email format typically follows the pattern of FLast@sylentis.com. Find more SYLENTIS email formats with LeadIQ.

When was SYLENTIS founded?

SYLENTIS was founded in 2006.

SYLENTIS

Q: What is SYLENTIS's official website and social media links?

SYLENTIS's official website is sylentis.com. SYLENTIS has social profiles on LinkedIn.

Q: How many employees does SYLENTIS have currently?

SYLENTIS has approximately 55 employees.

Q: What technology does SYLENTIS use?

SYLENTIS's tech stack includes Essential Addons for Elementor, spin.js, DPD, MySQL, Ubuntu.

Biotechnology ResearchCommunity of Madrid, Spain51-200 Employees

Sylentis is an European biotechnological company founded in 2006. Sylentis focuses on researching new therapeutic approaches based on gene silencing. Our company is specialised in developing ophtalmologic   therapies via interference RNA, a powerful tool for rational drug design.

Most advanced product of the company are treatments for glaucoma and dry eye syndrome.

Sylentis is a wholly owned member of PharmaMar (www.pharmamar.com)

Insights

Similar companies to SYLENTIS

Aptuit

Selvita

Immunocore

Axxam

SYLENTIS Tech Stack

Media & News

Sylentis hires Andreas Segerros as Chief Executive Officer.

SYLENTIS's Email Address Formats